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Therapeutic Amprenavir Concentrations in Cerebrospinal Fluid
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Benjamin B. Gelman,h Christina M. Marra,g Justin McArthur,i J. Allen McCutchan,b Susan Morgello,j David M. Simpson,j Lauren Way,d
Edmund Capparelli,c and Igor Grantd for the CHARTER Group

Antiretrovirals that reach higher concentrations in cerebrospinal fluid (CSF) are associated with better control of HIV in CSF
and possibly better neurocognitive performance. The objective of this study was to determine whether amprenavir (APV) concentrations in CSF are in the therapeutic range. Individuals were selected based on the use of regimens that included fosamprenavir (FPV), a prodrug of APV, and the availability of stored CSF and matched plasma. Total APV was measured in 119 matched
CSF-plasma pairs from 75 subjects by high-performance liquid chromatography (HPLC) (plasma) or liquid chromatography
tandem mass spectrometry (LC/MS/MS) (CSF). Concentrations were compared to the 50% inhibitory concentration (IC50) for
wild-type HIV (5.6 ng/ml). Subjects were predominantly middle-aged (median 44 years) white (57%) men (78%) with AIDS
(77%). APV was detected in all but 4 CSF specimens, with a median concentration of 24.8 ng/ml (interquartile range [IQR], 16.2
to 44.0). The median CSF-to-plasma ratio was 0.012 (IQR, 0.008 to 0.018). CSF concentrations correlated with plasma concentrations (rho ⴝ 0.61; P < 0.0001) and with postdose sampling interval (rho ⴝ ⴚ0.29; P ⴝ 0.0019). APV concentrations in CSF exceeded the median IC50 for wild-type HIV in more than 97% of CSF specimens with detectable APV by a median of 4.4-fold (IQR,
2.9 to 7.9). We conclude that administration of fosamprenavir should contribute to control of HIV replication in the central nervous system (CNS) as a component of effective antiretroviral regimens.

T

he central nervous system (CNS) is infected early in the course
of HIV disease, and HIV RNA is often detected in the cerebrospinal fluid (CSF) of untreated individuals with chronic disease.
CNS infection can lead to HIV-associated neurocognitive disorders (HAND), which remain common despite potent combination antiretroviral therapy (ART) (8). HIV and the resulting immune and glial responses are likely to be important factors in the
pathogenesis of HAND, leading to structural and functional synaptodendritic changes (15). Supporting the importance of the virus in the pathogenesis of HAND, HIV RNA concentrations in
CSF are higher in patients with cognitive impairment than in
those without impairment in cross-sectional and longitudinal
studies (6, 7, 16), although the association has weakened in the
highly active ART (HAART) era (20).
Antiretroviral drugs differ in their distribution— or penetration—into the CNS, with some drugs penetrating at concentrations similar to those in plasma and others penetrating at less than
1% of those in plasma. Only antiretrovirals that reach therapeutic
concentrations in the CNS should be able to reduce HIV replication in that compartment. Factors such as molecular weight, liposolubility, protein binding, and transmembrane transport all affect CNS penetration of antiretrovirals. Antiretrovirals that reach
higher levels in CSF are associated with better control of HIV
replication (10, 14) and often with better neurocognitive performance (4, 12, 13, 21), although not all reports agree (14).
HIV protease inhibitors are highly bound to plasma proteins
and are substrates for P-glycoprotein (9). Perhaps as a result, protease inhibitors have the lowest fractional penetrance (i.e., the
amount of drug reaching the CSF compartment) into CSF of the
antiretroviral drug classes. The limited distribution of protease
inhibitors into the CNS may be mitigated by the substantial potency of these drugs. One protease inhibitor, fosamprenavir
(FPV), a phosphorylated prodrug of amprenavir (APV), has low
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plasma protein binding (90%) relative to other drugs in its class.
The objectives of this study were to measure APV concentrations
in CSF, to compare them with matched plasma concentrations,
and to estimate the efficacy of APV in the CNS by comparing the
drug’s concentrations in CSF to the in vitro 50% inhibitory concentration (IC50) range for wild-type HIV-1.
MATERIALS AND METHODS
CSF-plasma specimen pairs were selected from subjects who had HIV-1
infection and who had enrolled in parent observational cohort studies
conducted at or coordinated by the University of California, San Diego,
between July 2004 and January 2009. An optional lumbar puncture was
part of the design of those parent studies. These cohort studies included
the CNS HIV AntiRetroviral Therapy Effects Research (CHARTER) and
the California NeuroAIDS Tissue Network (CNTN) projects. Selection
criteria included use of FPV and availability of stored CSF and matched
plasma obtained within 16 h (for FPV twice-daily [BID] dosing) and 24 h
(for FPV once-daily dosing) of self-reported dosing. Oral FPV was dosed
at 700 mg twice daily with ritonavir (RTV) 100 mg twice daily (n ⫽ 62),
1,400 mg once daily with ritonavir 200 mg once daily (n ⫽ 34), or 1,400
mg twice daily without RTV (n ⫽ 23). The UCSD Human Research Protections Program approved this research. Informed consent was obtained
from all subjects.
CSF was obtained by lumbar puncture performed with an aseptic
technique using a 22-gauge pencil-point needle by experienced operators.
Blood was obtained within 1 h of CSF by routine phlebotomy. All speci-
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RESULTS

A total of 119 CSF-plasma pairs were obtained from 75 subjects.
Most subjects provided either one (n ⫽ 52) or two (n ⫽ 14) specimen pairs. The remaining 9 subjects provided 3 (n ⫽ 5), 4 (n ⫽
1), 5 (n ⫽ 1), 6 (n ⫽ 1), and 9 (n ⫽ 1) pairs. Subjects were predominantly middle-aged (median age of 44 years; interquartile
range [IQR], 39 to 51) white (57%) men (78%) with AIDS (77%).
The median CD4⫹ cell count at the time of sampling was 413/
mm3 (IQR, 279 to 542), with 11% of values falling below 200/
mm3. The median nadir CD4⫹ cell count was 105/mm3 (IQR, 15
to 227). Disease severity based on the 1993 Centers for Disease
Control and Prevention classification system was categorized as C
for 56%, B for 30%, and A for 14%. HIV RNA was at or below the
detection limit (1.70 log10 copies/ml) in 57% of plasma and 88%
of CSF specimens.
The median duration of FPV use was 9.5 months (IQR, 3.1 to
20.1). Concurrent antiretrovirals included nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs) in all subjects, a nonNRTI in 13%, an additional protease inhibitor other than ritonavir in 11%, and one fusion inhibitor in 1%. The self-reported FPV
dose before sampling was taken with food at 83% of the sampling
time points. Adherence information was available for 85 sampling
time points, and adequate adherence was reported for 75 (87%).
APV concentrations in plasma and CSF are displayed in Fig. 1,
and aggregate data are summarized in Table 1, including both
overall results and results by FPV dosing schedule. APV was not
detected in four CSF specimens, while the corresponding plasma
had detectable APV. The median CSF APV concentrations with
and without RTV (including both FPV dosing schedules) were
26.1 ng/ml (IQR, 16.9 to 45.8) (not shown in table) and 23.4 ng/ml
(IQR, 10.7 to 41.5), respectively. The data for the timing of CSF
sampling were evenly distributed over the dosing intervals, and
the median postdose sampling intervals (⫾ standard deviation
[SD]) were 7.2 ⫾ 5.2 h for CSF and 6.9 ⫾ 5.2 h for plasma. APV
was detectable in all but four CSF specimens. CSF fractional penetrance (i.e., the amount of drug reaching the CSF compartment)
was 1.2% of the median total plasma APV concentration (IQR,
0.8% to 1.8%). APV concentrations in CSF correlated with those
in plasma (rho ⫽ 0.61; P ⬍ 0.0001) (Fig. 2) with persistent statis-
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FIG 1 Amprenavir concentrations by fosamprenavir dosing schedule in
plasma (dark shading) and CSF (light shading) by postdose sampling time.
The horizontal solid line represents the median IC50 (5.6 ng/ml) and the horizontal dashed line the IC50 99th percentile (16.7 ng/ml). Plasma concentrations below 300 ng/ml and corresponding CSF data were excluded from the
graph.

tical significance in subgroups with (rho ⫽ 0.63; P ⬍ 0.0001) and
without (rho ⫽ 0.57; P ⫽ 0.005) RTV. Further, correlations remained consistently strong when correlative analyses were performed using postdose sampling interval quartiles ranging from
0.5 to 5, 5 to 7, 7 to 12, and 12 to 23 h. The correlation weakened
slightly for the shortest postdose sampling interval range of 0.5 to
5 h, but the coefficient (rho ⫽ 0.30) was greater than 0.25 although
not statistically significant (P ⫽ 0.123). APV concentrations in
plasma and CSF correlated with the postdose sampling interval
(rho ⫽ ⫺0.25 [P ⫽ 0.0054] and ⫺0.29 [P ⫽ 0.0019], respectively).
The CSF-to-plasma ratio did not change significantly across the
dosing interval (rho ⫽ ⫺0.12; P ⫽ 0.22). RTV-boosted FPV regimens were associated with higher plasma concentrations of APV
compared to FPV without RTV (t ⫽ 1.61; P ⫽ 0.058) but not with
higher CSF concentrations (t ⫽ 1.07; P ⫽ 0.15). These results were
not substantially different when the analyses were performed with
inclusion of a single time point for subjects with multiple CSFplasma pairs.
APV concentrations in CSF exceeded the median IC50 for wildtype HIV-1 in 97.3% of specimens with detectable APV by a median of 4.4-fold (IQR, 2.9 to 7.9), while 73.9% of the same specimens had concentrations above the 99th percentile of the IC50
range. Higher APV concentrations in plasma were not associated
with undetectable HIV RNA levels in plasma (t ⫽ 0.42; P ⬎ 0.34).
Overall, higher APV concentrations in CSF were not associated
with undetectable HIV RNA in CSF (t ⫽ 1.5; P ⫽ 0.15). Of note, all
HIV RNA levels in CSF were undetectable when HIV RNA levels
in plasma were undetectable. In the subgroup of subjects who had
detectable HIV RNA levels in plasma, detectable HIV RNA levels
in CSF trended toward an association with lower APV concentrations in CSF (mean, 24.5 versus 37.5 ng/ml [t ⫽ ⫺1.8; P ⫽ 0.08]).
This association was present (␤ ⫽ 0.04; P ⫽ 0.08) in multivariable
analyses that accounted for APV concentrations in plasma, duration of FPV therapy, and postdose sampling time. Classification
and regression trees showed that all of the detectable HIV RNA
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mens were stored at ⫺70°C until analysis. Total APV was measured by
high-performance liquid chromatography (HPLC) (in plasma) and liquid
chromatography tandem mass spectrometry (LC/MS/MS) (in CSF). The
dynamic ranges of these assays were 3.9 to 2,000 ng/ml (plasma) and 0.39
to 200 ng/ml (CSF). APV concentrations in CSF were compared to the in
vitro IC50 range for wild-type HIV, including the median (5.6 ng/ml) and
the 99th percentile (16.7 ng/ml) of the IC50 range (17). HIV RNA was
quantified by reverse transcription-PCR using a Roche TaqMan RealTime
assay (Roche Diagnostics) with a lower limit of detection of 50 copies/ml
(1.7 log10 copies/ml). Peripheral blood CD4⫹ T cells were counted by flow
cytometry. Adequate adherence was defined as subjects taking ⬎95% of
their scheduled antiretroviral drugs over 4 days preceding the CSF and
blood specimen collection and was based on self-reporting. Data were
analyzed with descriptive, bivariable, and multivariable statistics using
standard methods (JMP; SAS Institute, Cary, NC). Spearman’s correlation coefficient was used to assess the relationship between plasma and
CSF APV concentrations. Descriptive statistics were calculated using all
data available. To eliminate bias due to interindividual differences in the
numbers of CSF-plasma pairs, certain statistical analyses, such as the analysis comparing dosing schedule to APV concentrations, were limited to
one time point per subject. By convention, we selected the earliest time
point for each subject for these analyses.

Therapeutic Amprenavir Concentrations in CSF

TABLE 1 Summary of amprenavir concentrations and sampling by fosamprenavir dosing schedule
Amprenavir concn (ng/ml) or IQR
Parameter

IQR
FPV 700 mg BID, with RTV
FPV 1,400 mg once a day, with RTV
FPV 1,400 mg BID, no RTV
Overall

Plasma (overall)

CSF-to-plasma ratio
or IQR

CSF-to-IC50 ratio
or IQR

60
33
22
115

62
34
23
119

60
33
22
115

60
33
22
115

31.6
20.5
23.4
24.8

2,230
2,460
1282
2,261

0.014
0.010
0.018
0.012

4.2
3.7
5.6
4.4

18.3–51
14.9–35.2
10.7–41.5
16.2–44.0

1,459–3,559
1,556–3,185
718–3,108
1,397–3,353

0.009–0.018
0.007–0.012
0.008–0.031
0.008–0.018

1.9–7.4
2.7–6.3
3.3–9.1
2.9–7.9

levels in CSF occurred in subjects who had APV concentrations in
CSF below 53.5 ng/ml. This equated to a CSF-to-IC50 ratio of 9.6.
In other words, all detectable HIV RNA levels in CSF occurred in
subjects whose APV concentrations in CSF exceeded the 50% inhibitory concentration by less than 9.6-fold. This categorical expression of CSF APV concentrations was statistically significantly
associated with detectable HIV RNA levels in CSF (␤ ⫽ ⫺12.5;
P ⫽ 0.01) in multivariable analyses that accounted for APV concentrations in plasma, duration of FPV therapy, and postdose
sampling time.
FPV dosing schedules were associated with different CSF and
plasma APV concentrations as well as CSF-to-plasma and CSF-toIC50 ratios as shown in Table 1 and Fig. 3. While FPV at 700 mg
BID with RTV resulted in the highest median CSF APV concentration, the other FPV dosing schedules did not substantially differ. However, FPV at 1,400 mg BID without RTV had the highest
CSF-to-plasma ratio, with trends toward significance (Fig. 3). FPV

FIG 2 Correlation between amprenavir CSF and plasma concentrations.
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at 1,400 mg BID without RTV appeared to be associated with
lower plasma APV concentrations, although the differences compared to other dosing schedules were not statistically significant.
DISCUSSION

APV CSF concentrations have not been reported previously other
than in a much smaller series with a median CSF APV concentration comparable to the one reported here (19). In this study, APV
concentrations in plasma were somewhat variable whereas APV
concentrations in CSF were more stable and exceeded the median
concentration required to inhibit wild-type HIV in vitro in nearly
all specimens regardless of dosing schedules (median, 4.4-fold

FIG 3 CSF-to-plasma ratios of amprenavir concentrations by fosamprenavir
dosing schedule, including only the first time point for subjects with multiple
time points. QD, once daily.
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Regimen
FPV 700 mg BID, with RTV
FPV 1,400 mg once a day, with RTV
FPV 1,400 mg BID, no RTV
Total
Median
FPV 700 mg BID, with RTV
FPV 1,400 mg once a day, with RTV
FPV 1,400 mg BID, no RTV
Overall

CSF

Croteau et al.
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CSF early in the postdose interval were no more likely to use one
dosing schedule of FPV than another.
Compared to other protease inhibitors, FPV appears to have
intermediate distribution into the CNS based on fractional penetrance (higher than atazanavir penetrance and lower than indinavir or darunavir penetrance). APV’s CSF-to-IC50 ratio is numerically lower than that of lopinavir, darunavir, or indinavir and
higher than that of atazanavir, but the clinical value of this measure is unproven (2, 3, 11). Even though APV has the lowest molecular weight of the HIV protease inhibitors currently in use and
a relatively high unbound fraction— characteristics that should
favor excellent CSF distribution—these characteristics may be
mitigated by APV’s average liposolubility relative to those of other
protease inhibitors and the P-glycoprotein active efflux transporter’s affinity for APV. Despite these findings, more than 97% of
CSF specimens had APV concentrations that exceeded the median
IC50 for wild-type HIV, almost 75% of concentrations were above
the 99th percentile of the IC50 range, and nearly 90% of CSF specimens had undetectable HIV RNA (often when HIV RNA was
detectable in plasma), supporting the idea of APV’s antiviral effectiveness in the CNS, although other antiretrovirals may have
been contributing to those findings.
In summary, our findings provide supporting evidence that
APV reaches therapeutic concentrations in the CNS and, therefore, that FPV should be an effective component of antiretroviral
regimens that aim to control HIV replication in this pharmacologically restricted compartment. The data presented in this report support an intermediate position for fosamprenavir relative
to other protease inhibitors in terms of CNS penetration effectiveness, but this conclusion requires validation with a clinical trial
that would directly compare FPV to another protease inhibitor(s).
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